Biostate AI, a Palo Alto, CA-based scalable biodata foundry startup, raised $4M in funding.
The round was led by Matter Venture Partners, with participation from Vision Plus Capital, Catapult VC, the Caltech Seed Fund, Dario Amodei (CEO of Anthropic), Joris Poort (CEO of Rescale), Michael Schnall-Levin (CTO of 10X Genomics) and Emily Leproust (CEO of Twist Bioscience).
The company intends to use the funds to expand operations and its development efforts.
Led by CEO David Zhang, Biostate AI is a startup founded in 2023 with the mission of developing generative AI that can benefit all of human health. Its Total RNA sequencing uses patent-pending Barcode-Integrated Reverse Transcription (BIRT) technology to analyze all types of RNA, including long non-coding RNAs (lncRNAs), micro RNAs (miRNAs), circular RNAs (circRNAs), and enhancer RNAs (eRNAs).
The company also launched OmicsWeb Copilot, a conversational AI launched to help biologists analyze and visualize data. Copilot leverages large-language models (LLMs) to understand user requests and intent to build customized software and scripts for data analysis. In addition to analyzing the user’s own uploaded data, it provides access to over 1000 unique RNAseq datasets collected by the Biostate team.
With offices and laboratories in Palo Alto, CA and Houston, TX, Biostate AI collaborates with academic, nonprofit, and industry partners on technology development and multiomic biodata collection.
Commenting on the news, David Zhang said: “Biostate AI has developed the instrumental technologies to facilitate the collection of more biological data at lower costs. We are pleased to offer these capabilities to academic and industry partners and collaborators.”
FinSMEs
09/07/2024